Gufic Biosciences Limited (GUFICBIO.NS)
INR 343.3
(-3.13%)
INR 343.3
(-3.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.59 Billion INR | 9.08% |
| 2022 | 5.13 Billion INR | 103.48% |
| 2021 | 2.52 Billion INR | 15.4% |
| 2020 | 2.18 Billion INR | -16.04% |
| 2019 | 2.6 Billion INR | 27.52% |
| 2018 | 2.04 Billion INR | 11.85% |
| 2017 | 1.82 Billion INR | 37.35% |
| 2016 | 1.32 Billion INR | 12.41% |
| 2015 | 1.18 Billion INR | 18.02% |
| 2014 | 1 Billion INR | 17.96% |
| 2013 | 849.36 Million INR | 26.43% |
| 2012 | 671.82 Million INR | 23.01% |
| 2011 | 546.13 Million INR | 29.53% |
| 2010 | 421.61 Million INR | 10.56% |
| 2009 | 381.33 Million INR | 24.19% |
| 2008 | 307.05 Million INR | -6.15% |
| 2007 | 327.18 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -5.32 Billion INR | -195.1% |
| 2023 Q2 | 5.78 Billion INR | 0.0% |
| 2023 FY | 5.59 Billion INR | 9.08% |
| 2023 Q4 | 5.59 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q4 | 5.13 Billion INR | 0.0% |
| 2022 FY | 5.13 Billion INR | 103.48% |
| 2022 Q2 | 3.85 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.52 Billion INR | 15.4% |
| 2021 Q2 | 2.83 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 2.52 Billion INR | 0.0% |
| 2020 Q2 | 2.58 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 2.18 Billion INR | -16.04% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 2.18 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 2.6 Billion INR | 27.52% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 2.24 Billion INR | 0.0% |
| 2019 Q4 | 2.6 Billion INR | 0.0% |
| 2018 Q4 | 2.04 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 1.94 Billion INR | 0.0% |
| 2018 FY | 2.04 Billion INR | 11.85% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 1.82 Billion INR | 37.35% |
| 2017 Q4 | 1.82 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.74 Billion INR | 0.0% |
| 2016 Q2 | 1.39 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 1.32 Billion INR | 12.41% |
| 2016 Q4 | 1.32 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 1.18 Billion INR | 18.02% |
| 2015 Q4 | 1.18 Billion INR | 0.0% |
| 2015 Q2 | 1.2 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.05 Billion INR | 0.0% |
| 2014 FY | 1 Billion INR | 17.96% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 1 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 822.33 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 849.36 Million INR | 0.0% |
| 2013 FY | 849.36 Million INR | 26.43% |
| 2012 FY | 671.82 Million INR | 23.01% |
| 2012 Q4 | 671.82 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 658.52 Million INR | 0.0% |
| 2011 FY | 546.13 Million INR | 29.53% |
| 2011 Q4 | 546.13 Million INR | 0.0% |
| 2010 FY | 421.61 Million INR | 10.56% |
| 2009 FY | 381.33 Million INR | 24.19% |
| 2008 FY | 307.05 Million INR | -6.15% |
| 2007 FY | 327.18 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -225.157% |
| Aarti Drugs Limited | 11.5 Billion INR | 51.323% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 32.129% |
| Ajanta Pharma Limited | 10.71 Billion INR | 47.716% |
| Alembic Limited | 1.43 Billion INR | -291.021% |
| Alkem Laboratories Limited | 48.6 Billion INR | 88.479% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 65.59% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -52.954% |
| Bal Pharma Limited | 2.51 Billion INR | -122.987% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1838.999% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -165.538% |
| Brooks Laboratories Limited | 248.6 Million INR | -2152.529% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -758.499% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -59.739% |
| Divi's Laboratories Limited | 18.99 Billion INR | 70.512% |
| Eris Lifesciences Limited | 38.26 Billion INR | 85.367% |
| Granules India Limited | 22.95 Billion INR | 75.605% |
| Ind-Swift Limited | 13.45 Billion INR | 58.375% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1786.983% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 47.704% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 90.861% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -769.694% |
| Medicamen Biotech Limited | 940.36 Million INR | -495.492% |
| Medico Remedies Limited | 438.24 Million INR | -1177.784% |
| Wockhardt Limited | 39.87 Billion INR | 85.955% |
| Orchid Pharma Limited | 3.84 Billion INR | -45.674% |
| RPG Life Sciences Limited | 1.38 Billion INR | -305.725% |
| Shilpa Medicare Limited | 12.93 Billion INR | 56.7% |
| Sigachi Industries Limited | 2.53 Billion INR | -121.226% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 60.262% |
| Unichem Laboratories Limited | 8.06 Billion INR | 30.603% |
| Vaishali Pharma Limited | 371.16 Million INR | -1408.72% |
| Wanbury Limited | 3.15 Billion INR | -77.461% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 92.2% |
| FDC Limited | 3.7 Billion INR | -50.971% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -614.422% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -15.041% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 94.765% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -8.086% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -144.591% |
| Laurus Labs Limited | 42.71 Billion INR | 86.89% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -183.347% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 50.082% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -3404.459% |
| Hester Biosciences Limited | 3.59 Billion INR | -55.779% |
| Ipca Laboratories Limited | 33.74 Billion INR | 83.404% |
| Venus Remedies Limited | 1.39 Billion INR | -302.054% |
| ZIM Laboratories Limited | 2.08 Billion INR | -169.123% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 96.321% |
| Morepen Laboratories Limited | 4.45 Billion INR | -25.562% |
| Neuland Laboratories Limited | 5.49 Billion INR | -1.841% |
| Sequent Scientific Limited | 8.27 Billion INR | 32.322% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -175.279% |
| Valiant Laboratories Limited | 1.05 Billion INR | -429.152% |
| Windlas Biotech Limited | 1.76 Billion INR | -217.684% |
| Hikal Limited | 12.99 Billion INR | 56.908% |
| Innova Captab Limited | 4.89 Billion INR | -14.285% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -118.64% |
| Themis Medicare Limited | 1.88 Billion INR | -196.677% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 11.52% |
| Mankind Pharma Limited | 23.87 Billion INR | 76.545% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 91.4% |
| Sakar Healthcare Limited | 1.26 Billion INR | -343.275% |
| Albert David Limited | 1.15 Billion INR | -386.896% |
| Lupin Limited | 96.23 Billion INR | 94.181% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 96.949% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -421.133% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -380.583% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.001% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 93.175% |
| NATCO Pharma Limited | 10.53 Billion INR | 46.831% |
| Suven Life Sciences Limited | 148.62 Million INR | -3667.846% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -88.298% |
| Strides Pharma Science Limited | 37.68 Billion INR | 85.139% |
| Indoco Remedies Limited | 10.34 Billion INR | 45.855% |
| Alpa Laboratories Limited | 307.12 Million INR | -1723.318% |
| Lasa Supergenerics Limited | 541.92 Million INR | -933.318% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -43.847% |